Citations

Clear

9383 citation(s) found for "Thomas, PS".

Impact of Tricuspid Regurgitation on the Clinical Outcomes of Patients with Heart Failure -- United States Population-Based Survey Analysis
Almani, Muhammad Usman , Khan, Rasha , Yousuf, Muhammad , Amanullah, Aman, Yousuf, Muhammad , Fatima, Noor E

Mayo Clinic

No container title available | January 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.173798712.20712210/v1 Get It

Background: Tricuspid regurgitation (TR) is a common occurrence in patients with heart failure (HF), and its role in disease progression has gained attention in recent years. While TR can worsen the clinical outcomes in HF patients, its impact on gender, racial and socioeconomic factors remains largely unexplored. With growing evidence supporting the role of percutaneous interventions for the treatment of significant TR, understanding these disparities is more crucial than ever. Methods: Data was extracted from the National Inpatient and National Readmission 2016 - 2020 Databases. We used ICD-10 code I50 to identify the patients primarily admitted for HF and subdivided the cohort into two groups based on presence or absence of TR. We performed multivariable Logistic regression analysis to determine odds of in-hospital mortality and multivariable Cox regression analysis to assess 30- and 90-day hospital readmission in HF patients with and without TR. All the analyses were adjusted for age, gender, insurance status, Charlson co-morbidity index (CCI) and hospital characteristics. STATA 16 software was used for analysis. Results: There was no difference in in-hospital mortality among HF patients with and without TR (OR: 1.04, 95% CI 0.94 – 1.16, p = 0.442) except in certain subgroups of HF patients. HF patients with TR were 6% more likely to have HF-specific readmission in 30-days (HR: 1.06, 95% CI 1.00 – 1.13, p = 0.044) and 9% more likely to have HF-specific readmission in 90-days (HR: 1.09, 95% CI 1.03 – 1.15, p = 0.002). Subgroup analysis revealed significant gender, racial and socioeconomic disparities in in-hospital mortality and readmission outcomes of HF patients with TR compared to those without TR. Conclusion: In our population-based survey analysis, we observed significant gender, racial and socioeconomic disparities in clinical outcomes of HF patients with TR compared to those without TR.
Dynamicasome! Comprehensive Mutational Analysis and AI-Driven Prediction of PMM2 Pathogenicity: Integrating Molecular Dynamics Simulations with Machine Learning Models
Islam, Naeyma N., Fuller, Jessica , Weber, Caleb, Chitale, Rohit , Jussila, Benjamin , Coban, Matt , Fuller, Jessica M. , Weber, Caleb, Brock, Trisha , Tao, Cui , Caulfield, Thomas R.

Mayo Clinic

No container title available | January 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5538161/v1 Get It

Abstract Advances in genomic medicine have accelerated the identification of mutations in disease- associated genes, but the pathogenicity of many mutations remains unknown, hindering their use in diagnostics and clinical decision-making. Predictive AI models have been generated to combat this issue, but current tools display low accuracy when tested against functionally validated datasets. We show that integrating detailed conformational data extracted from molecular dynamics simulations (MDS) into advanced AI-based models can increase their predictive power. We carried out an exhaustive mutational analysis of the disease gene PMM2 and subjected structural models of each variant to MDS. AI models trained on this dataset outperformed existing tools when predicting the known pathogenicity of mutations. Our best performing model, a neuronal networks model, was also able to predict the pathogenicity of several PMM2 mutations currently considered of unknown significance. We believe this new model will help alleviate the burden of unknown variants in genomic medicine.
Clinical outcomes of patients with unsuccessful mechanical thrombectomy versus best medical management of medium vessel occlusion stroke in the middle cerebral artery territory
Faizy, Tobias D. , Yedavalli, Vivek , Salim, Hamza , Lakhani, Dhairya A. , Musmar, Basel , Adeeb, Nimer , Essibayi, Muhammed Amir , Daraghma, Motaz , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Puri, Ajit S., Dyzmann, Christian , Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Jabbour, Pascal , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus A, Costalat, Vincent , Gory, Benjamin, Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Valente, Iacopo , Salim, Hamza , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Colasurdo, Marco , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Siegler, James E , Nguyen, Thanh N , Altschul, David J , Gonzalez, Nestor R , Hecker, Constantin , Marnat, Gaultier , Shaikh, Hamza A , Griessenauer, Christoph J , Liebeskind, David S. , Alexandre, Andrea M , Kalsoum, Erwah , Mendes Pereira, Vitor , Dmytriw, Adam A , Guenego, Adrien , Heit, Jeremy J , Musmar, Basel , Regenhardt, Robert W , Lakhani, Dhairya , Essibayi, Muhammed Amir , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Siegler, James E. , Nguyen, Thanh N. , Möhlenbruch, Markus , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Wintermark, Max , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | January 23, 2025 | Volume: 18 | Issue: 1 | Pages: 155-165

10.1136/jnis-2024-022642 | PMID 39855674 Get It

Background Current randomized controlled trials are investigating the efficacy and safety of mechanical thrombectomy (MT) in patients with medium vessel occlusion (MeVO) stroke. Whether best medical management (MM) is more efficient than unsuccessful vessel recanalization during MT remains unknown. Methods This was a retrospective cohort study using data from 37 academic centers across North America, Asia, and Europe between September 2017 and July 2021. Only patients with occlusion of the distal branches (M2 and M3) of the middle cerebral artery territory were included. Unsuccessful MT was defined as a modified Thrombolysis in Cerebral Infarction score of 0–2a. Propensity score matching was used to control for confounders. The primary outcome was functional independence, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after treatment. Multivariable regression analysis was used to assess factors associated with the primary outcome. Results Of 2903 patients screened for eligibility, 532 patients were analyzed (266 per group) after propensity score matching. The MM group had superior functional outcomes, with 32% achieving mRS 0–1 at 90 days compared with 21% in the MT group (P=0.011). Patients in the MM group also had significantly lower rates of symptomatic intracranial hemorrhage (sICH) (3.4% vs 16%, P<0.001) and any hemorrhage (18% vs 48%, P<0.001). On multivariable regression, unsuccessful MT was associated with reduced odds of functional independence (OR 0.50, 95% CI 0.29 to 0.85, P=0.011) and increased odds of sICH (OR 4.32, 95% CI 1.84 to 10.10, P<0.001). Mortality rates were similar between groups (27% in MM vs 29% in MT, P=0.73). Conclusion Unsuccessful MT for MeVO was linked to worse outcomes than best MM. These findings highlight the risks of prolonged attempts and emphasize the importance of efficient procedural decision-making to reduce complications and improve patient outcomes.
Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S.
Desai, Aakash , Sehgal, Priya , Khataniar, Himsikhar , Lewis, James D. , Lichtenstein, Gary R. , Kochhar, Gursimran , Desai, Aakash , Sehgal, Priya , Lewis, James D , Farraye, Francis A.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 23, 2025 | Volume: 61 | Issue: 7 | Pages: 1197-1207

10.1111/apt.18513 | PMID 39844347 Get It

ABSTRACT Background Obesity has been linked to a more severe phenotype in patients with ulcerative colitis (UC). Aim To evaluate the impact of obesity on outcomes of advanced therapies in UC. Methods We conducted a retrospective cohort study utilising the TriNetX database comparing the composite score of corticosteroid use, change in advanced therapy or colectomy within two years between two cohorts of patients with UC—those with obesity (BMI ≥ 30 kg/m 2 ) and those without (BMI 18.5–24.9). The risk assessment was stratified to specific advanced therapies, including tumour necrosis factor α inhibitors (TNFi), vedolizumab, ustekinumab and Janus kinase inhibitors (JAKi). We performed 1:1 propensity score matching (PSM) for demographics, co‐morbid conditions, laboratory values and IBD medications including corticosteroids. Results There were 3904, 2025, 1150 and 477 patients on TNFi, vedolizumab, ustekinumab and JAKi, respectively, in the UC obesity cohort. After PSM, the UC obesity cohort was at an increased risk of the composite outcome of corticosteroid use, change in therapy and colectomy compared to the UC control cohort in patients on TNFi (aHR 1.37, 95% CI 1.29–1.49), vedolizumab (aHR 1.29, 95% CI 1.16–1.43), ustekinumab (aHR 1.1.26, 95% CI 1.10–1.44) and JAKi (aHR 1.38, 95% CI 1.13–1.69). Sub‐group analysis based on the specific TNFi also showed an increased risk of composite outcome for infliximab (aHR 1.36, 95% CI 1.22–1.52) and adalimumab (aHR 1.26, 95% CI 1.11–1.42) within 2 years. Conclusions Obesity is associated with lower efficacy of several advanced therapies in patients with UC.
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Lacchetti, Christina , Armstrong, Deborah K. , Cliby, William A. , Edelson, Mitchell I. , García, Agustin A. , Ghebre, Rahel G., Gressel, Gregory M. , Lesnock, Jamie , Meyer, Larissa A. , Moore, Kathleen N. , Olawaiye, Alexander , Salani, Ritu , Sparacio, Dee, Tew, William P. , Gaillard, Stéphanie , Lacchetti, Christina , Armstrong, Deborah K , Cliby, William A , Gangi, Alexandra , Gressel, Gregory M , Meyer, Larissa A , Moore, Kathleen , O'Cearbhaill, Roisin E , Salani, Ritu , van Driel, Willemien J , Tew, William P , Edelson, Mitchell I , Gaillard, Stéphanie , Ghebre, Rahel G.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2025 | Volume: 43 | Issue: 7 | Pages: 868-891

10.1200/jco-24-02589 | PMID 39841949 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer (epithelial ovarian cancer [EOC]). METHODS A multidisciplinary Expert Panel convened and updated the systematic review. RESULTS Sixty-one studies form the evidence base. RECOMMENDATIONS Patients with suspected stage III-IV EOC should be evaluated by a gynecologic oncologist, with cancer antigen 125, computed tomography of the abdomen and pelvis, and chest imaging included. All patients with EOC should be offered germline genetic and somatic testing at diagnosis. For patients with newly diagnosed advanced EOC who are fit for surgery and have a high likelihood of achieving complete cytoreduction, PCS is recommended. For patients fit for PCS but deemed unlikely to have complete cytoreduction, NACT is recommended. Patients with newly diagnosed advanced EOC and a high perioperative risk profile should receive NACT. Before NACT, patients should have histologic confirmation of invasive ovarian cancer. For NACT, a platinum-taxane doublet is recommended. Interval cytoreductive surgery (ICS) should be performed after ≤four cycles of NACT for patients with a response to chemotherapy or stable disease. For patients with stage III disease, good performance status, and adequate renal function treated with NACT, hyperthermic intraperitoneal chemotherapy may be offered during ICS. After ICS, chemotherapy should continue to complete a six-cycle treatment plan with the optional addition of bevacizumab. Patients with EOC should be offered US Food and Drug Administration–approved maintenance treatments. Patients with progressive disease on NACT should have diagnosis reconfirmed via tissue biopsy. Patients without previous comprehensive genetic or molecular profiling should be offered testing. Treatment options include alternative chemotherapy regimens, clinical trials, and/or initiation of end-of-life care. Additional information is available at www.asco.org/gynecologic-cancer-guidelines . This guideline has been endorsed by the Society of Gynecologic Oncology.
Medialized vs. Lateralized Reverse Total Shoulder Arthroplasty for Proximal Humerus Fractures
Holt, K., Bindi, Victoria E. , Buchanan, Timothy R. , Reddy, Akshay , Tishad, Abtahi , Desai, Persis , Hones, Keegan M. , Wright, Thomas W. , King, Joseph J. , Holt, Kara E , Reddy, Akshay R , Schoch, Bradley S , King, Joseph J , Hao, Kevin A , Hones, Keegan M , Schoch, Bradley S. , Hao, Kévin A.

Mayo Clinic

JBJS Reviews | January 21, 2025 | Volume: 13 | Issue: 1 | Pages: No page available

10.2106/jbjs.rvw.24.00160 | PMID 39836775 Get It

Background: Reverse shoulder arthroplasty (RSA) is increasingly used in the treatment of proximal humerus fractures (PHFs) with reliable clinical improvement. Lateralized RSA implants have conferred superior outcomes compared with the original Grammont design in patients with nontraumatic indications. However, in the setting of a PHF, lateralized components can place increased tension across the tuberosity fracture site and potentially compromise tuberosity healing and outcomes. This systematic review and meta-analysis sought to determine the effect of implant design on clinical outcomes after RSA for PHFs. Methods: A systematic review was performed per Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed/MEDLINE, EMBASE, Web of Science, and Cochrane were queried for clinical studies on RSA performed for PHFs that reported implant manufacturer details. Our primary outcomes included postoperative external rotation (ER), forward elevation (FE), abduction, Constant score, rate of greater tuberosity (GT) healing, and the incidence of complications compared between medialized vs. lateralized global implant design. Results: Globally lateralized RSA cohorts (478 RSAs total with cumulative lateral offset achieved through humeral or glenoid lateralization or both humeral and glenoid lateralization) were found to have a greater mean postoperative Constant score compared with globally medialized (medialized glenoid and medialized humerus) RSA cohorts with 1,494 total medialized RSAs (66 vs. 59, p = 0.006), but there was no significant difference regarding mean postoperative ER (30° vs. 22°, p = 0.078), FE (117° vs. 119°, p = 0.708), or abduction (103° vs. 107°, p = 0.377). On meta-regression, neither implant design nor tuberosity status significantly influenced postoperative ER, FE, abduction, or Constant score on meta-regression independent of mean follow-up and age at surgery. The rate of GT healing was greater in lateralized compared with medialized RSAs (88% vs. 72%, p < 0.001). On meta-regression, medialized RSA design was associated with a 73% lower odds of GT healing (odds ratio = 0.27, 95% confidence interval = 0.11-0.68, p = 0.007) independent of mean follow-up and age at surgery. Conclusion: Lateralized RSA implants conferred no significant functional benefit over medialized implants when used in patients with PHFs. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
A Systematic Literature Review on the Burden of Disease for Patients With Moderate to Severe Acute Ischemic Stroke
Quinn, Terry , Kitagawa, Kazuo , Leung, Thomas , Molina, Carlos A. , Rabinstein, Alejandro, Bentley, Roy , Heuser, Maria, Nair, Vedes, Leung, Thomas , Rabinstein, Alejandro A. , Henry, Owen, Saver, Jeffrey L.

Mayo Clinic

Medicine | January 21, 2025 | Volume: 104 | Issue: 3 | Pages: e41249

10.1097/md.0000000000041249 | PMID 39836564 Get It

Background: A vast amount of literature is available on the burden of acute ischemic stroke (AIS). Yet, most information on AIS burden does not stratify by stroke severity, and the inclusion of mild strokes (National Institute of Health Stroke Scale < 5) might obscure the true impact of moderate-to-severe AIS. Therefore, it is important to understand the literature as it pertains to the epidemiological, clinical, humanistic, and economic burden of moderate-to-severe AIS from a global perspective. Methods: A systematic literature review (SLR) was conducted, including articles published between January 2015 and June 2023. The clinical burden search focused on patients with moderate or severe AIS. Due to the paucity of evidence, the humanistic and economic burdens were evaluated based on overall AIS studies. Abstract and full-text screening were conducted by 2 reviewers, with data extraction completed by 1 reviewer. In all, 136 studies were included in the SLR. Results: AIS caused a substantial burden for patients and the healthcare system. The clinical burden of AIS (specifically severe AIS) resulted in high mortality and worse functional outcomes across multiple demographics (female sex, older age, and patients with comorbidities). The economic burden of overall AIS was substantial, with inpatient costs as the primary driver (a mean or median stay of 7 days). The highest inpatient costs were reported in South Korea ($45,180) and the United States ($38,470). Conclusions: The review highlighted the huge burden of moderate-to-severe AIS, with patients experiencing worse outcomes with increased stroke severity. Further focus is needed on outcomes relating to moderate-to-severe AIS to fully understand the burden of stroke in this patient population.
ASRA Pain Medicine consensus practice infection control guidelines for regional anesthesia and pain medicine
Provenzano, David , Hanes, Michael, Hunt, Christine , Benzon, Honorio T. , Grider, Jay S., Cawcutt, Kelly , Doshi, Tina L , Hayek, Salim M. , Hoeltzer, Bryan, Johnson, Rebecca L. , Macfarlane, Alan , Neuman, Stephanie, Pawa, Amit , Pilitsis, Julie G. , Sivanesan, Eellan , Sondekoppam, Rakesh V. , Zundert, Jan Van , Provenzano, David Anthony , Hayek, Salim , Kopp, Sandra , Loftus, Randy W. , Macfarlane, Alan James Robert , Nagpal, Ameet S , Neuman, Stephanie A , Pawa, Amit , Pearson, Amy C S , Sivanesan, Eellan , Sondekoppam, Rakesh V , van Zundert, Jan , Narouze, Samer , Benzon, Honorio T , Cawcutt, Kelly , Johnson, Rebecca L , Doshi, Tina L , Hunt, Christine , Grider, Jay S. , Kalagara, Hari , Kopp, Sandra L. , Nagpal, Ameet , Pearson, Amy C. S. , Narouze, Samer

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2024-105651

10.1136/rapm-2024-105651 | PMID 39837579 Get It

Background To provide recommendations on risk mitigation, diagnosis and treatment of infectious complications associated with the practice of regional anesthesia, acute and chronic pain management. Methods Following board approval, in 2020 the American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) commissioned evidence-based guidelines for best practices for infection control. More than 80 research questions were developed and literature searches undertaken by assigned working groups comprising four to five members. Modified US Preventive Services Task Force criteria were used to determine levels of evidence and certainty. Using a modified Delphi method, >50% agreement was needed to accept a recommendation for author review, and >75% agreement for a recommendation to be accepted. The ASRA Pain Medicine Board of Directors reviewed and approved the final guidelines. Results After documenting the incidence and infectious complications associated with regional anesthesia and interventional pain procedures including implanted devices, we made recommendations regarding the role of the anesthesiologist and pain physician in infection control, preoperative patient risk factors and management, sterile technique, equipment use and maintenance, healthcare setting (office, hospital, operating room), surgical technique, postoperative risk reduction, and infection symptoms, diagnosis, and treatment. Consensus recommendations were based on risks associated with different settings and procedures, and keeping in mind each patient’s unique characteristics. Conclusions The recommendations are intended to be multidisciplinary guidelines for clinical care and clinical decision-making in the regional anesthesia and chronic interventional pain practice. The issues addressed are constantly evolving, therefore, consistent updating will be required.
Blood Culture Use in Medical and Surgical Intensive Care Units and Wards
Hsu, Yea‐Jen , Salinas, Alejandra , Gadala, Avinash , Bower, Chris , Degnan, Kathleen, Dhaubhadel, Pragya, Drees, Marci , Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glaser, Laurel , Johnson, J. Kristie, Kim, Justin , Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Robinson, Evan D. , Rodriguez‐Nava, Guillermo , Salinas, Jorge , Schrank, Gregory M. , Shah, Aditya , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Cosgrove, Sara E. , Fabre, Valeria , Carroll, Karen C. , Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Howard‐Anderson, Jessica , Mathers, Amy J. , Moehring, Rebekah W. , Nelson, George E. , O’Horo, John C. , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van

Mayo Clinic

JAMA Network Open | January 15, 2025 | Volume: 8 | Issue: 1 | Pages: e2454738

10.1001/jamanetworkopen.2024.54738 | PMID 39813030 Get It

ImportanceBlood culture (BC) use benchmarks in US hospitals have not been defined.ObjectiveTo characterize BC use in adult intensive care units (ICUs) and wards in US hospitals.Design, Setting, and ParticipantsA retrospective cross-sectional study of BC use in adult medical ICUs, medical-surgical ICUs, medical wards, and medical-surgical wards from acute care hospitals from the 4 US geographic regions was conducted. Critical access hospitals, less than 6 months of BC data, and non-US hospitals were excluded. The study included BC use data from September 1, 2019, to August 31, 2021. Data were analyzed from February 23 to July 14, 2024.Main Outcomes and MeasuresThe primary outcome was BC use per 1000 patient-days. Adjusted means with 95% CIs were calculated using mixed-effects negative binomial regression models adjusted for unit type, hospital bed size, geographic region, seasonality, and state COVID-19 case load, with random intercepts accounting for clustering at unit and hospital levels. Secondary outcomes included blood culture positivity, single BCs, BC contamination, and minimum threshold for BC use where blood culture positivity would be optimized.ResultsA total of 362 327 blood cultures were analyzed from 27 medical ICUs, 35 medical-surgical ICUs, 121 medical wards, and 109 medical-surgical wards from 48 hospitals in 19 states and the District of Columbia. The adjusted mean BC use per 1000 patient-days was 273.1 (95% CI, 270.2-275.9) for medical ICUs, 146.0 (95% CI, 144.5-147.5) for medical-surgical ICUs, 80.3 (95% CI, 79.8-80.7) for medical wards, and 65.1 for medical-surgical wards. Blood culture use was significantly higher across all 4 unit types in hospitals with more than 500 beds compared with 500 or less beds and in the West-Midwest compared with other regions. Single blood culture and positive blood culture rates were below 10% across all 4 unit types. Of the 292 units, 97% had a mean BC contamination rate within 3% of the recommended threshold, and 51% were within 1%. The minimum BC use thresholds (ie, BC use below this number may represent undertesting) were 120 BCs per 1000 patient-days for medical ICUs, 80 BCs per 1000 patient-days for medical-surgical ICUs, and 30 BCs per 1000 patient-days for medical-surgical wards.Conclusions and RelevanceThe findings of this study suggest that blood culture positivity may help determine appropriate BC use for individual unit types.